Bioactivity:

Ataluren is a novel, orally administered drug that targets nonsense mutations. Ataluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk.

CAS nr:

775304-57-9

Purity:

98%

Molecular Weight:

284,24

SMILES:

OC(=O)c1cccc(c1)-c1noc(n1)-c1ccccc1F

Formula:

C15H9FN2O3

Pathway:

Membrane transporter/Ion channel,Autophagy

Target:

CFTR,Autophagy